Drug Research
FDA And NIH Working Together To Discover More About ALS
The Critical Path for Rare Neurodegenerative Diseases (CP-RND), a new public-private partnership created to advance the development of treatments for amyotrophic lateral sclerosis (ALS) and similar rare neurodegenerative conditions, has been initiated by the US Food and Drug Administration...
Drug Research
Advanced Cancers Are Tackled By Genetically Altered Herpes
A quarter of patients with a variety of advanced tumours have shown signals of benefit from RP2, a modified form of the herpes simplex virus, according to research. The trial's participants had malignancies of the head and neck, oesophagus,...
Drug Research
EC Authorizes Opdualag From BMS As A Melanoma Treatment
The fixed-dose combination Opdualag (nivolumab and relatlimab) from Bristol Myers Squibb (BMS) has received clearance from the European Commission for use as the first-line therapy for advanced unresectable or metastatic melanoma.
Patients aged 12 years and older who have cancer...
Drug Research
Bluebird Hits $3m Mark With Gene Therapy After FDA Approval
Within one firm, the title of most costly treatment in the world has changed hands within a month.
Bluebird Bio has received an FDA fast clearance for Skysona, also known as eli-cel, for the uncommon neurological condition cerebral adrenoleukodystrophy (CALD),...
Drug Research
First Next-Gen Parkinsons Med To Be Made By Neuron23, QIAGEN
QIAGEN and Neuron23TM Inc., an early-stage biotechnology company focused on creating precision medications for genetically defined neurological and immunological illnesses, have announced a partnership to create a companion diagnostic for Neuron23's LRRK2 inhibitor for Parkinson's disease.
According to the terms...
Drug Research
Australia Permits New Treatment For Rare Bile Duct Cancer
Australia has authorised the use of a new targeted therapy for the treatment of cholangiocarcinoma, a rare bile duct cancer. The Therapeutic Goods Administration (TGA) has granted PEMAZYRE (pemigatinib) provisional approval for the treatment of adult patients with metastatic...
Drug Research
Beyfortus From Sanofi And Astrazeneca Is Supported By RSV
Beyfortus has received approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency to treat lower respiratory tract sickness caused by the respiratory syncytial virus (RSV) in neonates and young children.
If authorised, Beyfortus,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read